ストックスクリーナーアプリを入手
3.18
3.05%
-0.10
アフターアワーズ：
3.15
-0.03
-0.94%
前日終値:
$3.28
開ける：
$3.26
24時間の取引高:
8,959
Relative Volume:
0.37
時価総額：
$17.72M
収益：
-
当期純損益:
$-16.35M
株価収益率:
-1.0426
EPS:
-3.05
ネットキャッシュフロー:
$-11.88M
1週間 パフォーマンス:
-13.59%
1か月 パフォーマンス:
+3.58%
6か月 パフォーマンス:
-29.18%
1年 パフォーマンス:
-38.85%
1日の値動き範囲:
$3.00
$3.3499
1週間の範囲:
$3.00
$3.7299
52週間の値動き範囲:
$2.96
$11.79
Lipocine Inc Stock (LPCN) Company Profile
名前
Lipocine Inc
セクター
電話
801 994 7383
住所
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
LPCN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.18 | 17.72M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-06-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
| 2015-06-23 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Lipocine Inc (LPCN) 最新ニュース
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener
Revolutionary At-Home Postpartum Depression Drug Enters Final Testing Phase - Stock Titan
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights
Lipozem Reviews (2025): Consumer Reports on Lipozem Weight Loss Formula - GlobeNewswire Inc.
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow
Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan
Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com
Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune
Lipocine announces FDA labeling changes for testosterone products - TipRanks
FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine - StockTitan
Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World
LPCN stock touches 52-week low at $2.92 amid market challenges By Investing.com - Investing.com South Africa
LPCN stock touches 52-week low at $2.92 amid market challenges - Investing.com India
Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - Armenian Reporter
Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World
Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World
Lipocine plans phase 3 study for postpartum depression drug - MSN
Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com
Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal
Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
FDA fast tracks Lipocine's sarcopenia treatment - Investing.com
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire
FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online
Where are the Opportunities in (LPCN) - Stock Traders Daily
Lipocine Inc (LPCN) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):